Upload
chris-mulyo
View
248
Download
16
Embed Size (px)
DESCRIPTION
presentasi
Citation preview
CUTANEUS LYMPHOMA IN PATIENT WHO IS DIAGNOSED AS MORBUS
HANSEN AT BEGINNING
Hermawati AzikinA.Fachruddin Benyamin
Department of Internal MedicineMedical Faculty - Hasanuddin University
Case Report
BACKGROUND
Background
• Cutaneus lymphoma– Group of lymphoproliferative disorders: T & B
lymphocytes malignancy; part of extranodal NHL– In the US: CTCL incidence (1973-2002) 6.4/1
million people/yr– Adult & elderly people: average age 40-60 yr• Children & young people: sporadic case
– 80% manifested as CTCL
• Cutaneous T-cell lymphoma– In 1979, National Cancer Institute (NCI) introduced
CTCL: group of lymphoproliferative disorders characterized by the presence of neoplastic T cells in the skin
– Manifestations in the skin but in advanced stage can involved hematology, lymph nodes & visceral organs
– Etiology:• Unknown• Chromosome aberration, especially in advanced stage
CTCL
• WHO- EORTC classified CTCL into 2 subtypes : indolent & aggressive type
• Mycosis fungoides (MF)– Indolent subtype– The most common types of CTCL: 44%– Variant of MF (WHO/EORTC classification):• Sezary syndrome, folliculotropic MF, granulomatous
slack skin and pagetoid reticulosis (Woringer-Kolopp disease)
• The diagnosis of MF: history of the disease, clinical feature, histomorphologic & cytomorphologic feature, and cytogenetic examination
• Management of CTCL– Early stage: topical therapy w/wo interferon-α or
administration of oral agents– Advanced stage: chemotherapy
CASE REPORT
History Taking
• A male, 52 yo from Tual, admitted in Grestelina hospital with complaints patches on the skin all over the body
• First experienced 3 yrs ago, the patches & plaques raised on face, scalp, back, and chest initially, and then raised neck, body, and extremities
• In the course of illness:– fluid-filled lesions on the skin is reddish & fester– itchy patches & plaques especially when sweating– sometimes pain like puncture-pin
• Hair becomes brittle, pts had a hair loss and so did the eyebrows
• Subfebril fever during the disease but when admitted to Grestelina hospital no fever
• No cough, no history of contact with a cough person, no nausea, decreased of appetite, decreased of body weight. Defecation normal, micturation normal.
Previous Illness History
• 3 yrs ago: pts went to Dermatologist in Ambon & was diagnosed as Morbus Hansen wo any information about skin biopsy exam. He was given medication (drugs & topical) for 2 months
• History of contact with MH pts was denied, job was staff of PLN
• History drug user & free sex was denied. No DM, family history with the same disease was denied
• May 2013, the patient went to Ibnu Sina Dermatologist in Makassar– Skin biopsy results: skin malignancies– Therapy: methotrexate, oral and topical symptomatic therapy– Follow-up was carried out for 3 months with improved of
symptoms– No complete recovery, residence, & constraints to find time
for control discontinued methotrexate• Patches was recurred in all parts of the body especially
in chest, back & body fold• October 2013: pts was hospitalized in Grestelina with a
diagnosis of Cutaneous T-cell lymphoma/MF
Physical Exam
• Conscious/Adequate nutrition • Normal vital signs• Head– alopecia, red & black patches
on the scalp and face, side of the head look uneven shape, madarosis
• Neck : JVP R-2 cmH2O, no enlargement of lymph node, no tumor mass
• Thorax / Heart / Abdomen: Normal
• On the surface of the skin of all body & extremities: patches with hyperkeratosis plaque, excoriation & hypersquamation
• Fingernails especially the base of the finger was damaged & dull
Laboratory Exam
Oktober, 22nd 2013• WBC : 13.840 /µl• Hb : 11,1 gr/dl • PLT : 359.000 /µl• AST/ALT : 20/23 U/L• Ur/Cr : 5/0,60 mg/dl• ESR : 70 mm
Oktober, 31st 2013• WBC : 8.610 /µl• Hb : 11,4 g/dl• PLT : 207.000 /µl• Ur/Cr : 19,0/0,7 mg/dl• ESR : 40+/75+ mm
Abdominal US
Mei, 31st 2013 • Liver : enlarge with flat
surface, homogen echoparenchyme, no nodular lesion
• Impression : hepatomegaly
Histopathology
• Skin biopsy (July, 5th 2013)• Impression : cutaneus lymphoma (T-cell
lymphoma/mycosis fungoides)
• According to history taking, PE, & supporting exam, this pts was diagnosed as cutaneus T-cell lymphoma with mycosis fungoides type
DISCUSSION
DISCUSSION
• The pts was initially diagnosed as Morbus Hansen– skin lesion: patches & thickening of the skin as a plaques– damaged of hair follicles: alopecia– pain like punctured-pin: neuropathy– WITHOUT skin exam/biopsy
• In MH, skin manifestations: – diffuse erythema & thickening of the skin with infiltrates were
mainly found on the ears– face looks shiny & eyebrow usually be lost– hypopigmentation patches
• Granulomatous MF is a rare type of CTCL with a clinical picture that resembles lepromatous leprosy of MH
• Skin manifestations in early stage of MF– patchy hypopigmentation wo symptoms & lasts for several
years– no sensory defisit– skin lesions appear dry & dispigmentation multiple
ulcerated nodules– with anti-tuberculosis th/ in this pts no improvement,
which encourages further exam• After skin biopsy: CTCL• In the smear exam: no microorganisms• Histopathological exam: infiltrate of lymphocytes in
the dermis extending into the submucosa
WHO-EORTC Classification of Cutaneous Lymphoma
• CTCL:– Slow-growing cutaneus lymphoma– Psoriasiform or diffuse erythroderma lesions– Atypical lymphocytes in the circulation– Early stage: resemble other skin diseases so
difficult to enforce• There are 2 types: MF & Sezary syndrome• MF is the most common type of CTCL: 44%
Mycosis fungoides
• Malignant lymphoma characterized by the expansion of clon CD4 lymphocytes or T helper/T memory (CD45 + RO) which are normally present on the skin
• 1st introduced in 1806 by Alibert-Bazin, Dermatologist: severe disorder in the form of large tumors that undergo necrotic which resemble mushrooms
• The most common of CTCL (44%)– indolent type– 3 stages: patches (atrophic or non-atrophic), plaques sometimes
accompanied by lymphadenopathy, tumor that is susceptible to ulceration
– Lesion distribution: asymmetric & most often on the back, lower legs, groin, axilla & breast
Sezary syndrome
• Clinical symptoms & signs: skin edema, lymphadenopathy, hand & foot hyperkeratosis, alopecia, nail dystrophy, ectropion & organomegaly
• Skin lesions: hypopigmentation patch, erythematous with thickening of patches
• Aggressive type• 5% of all cases of MF
• In this pts also presented alopecia• Alopecia was experienced before pts got the
treatment– Alopecia was found in 2.5% of pts with CTCL– Folliculotropic MF– Infiltration of atypical lymphocytes in the epithelium
of hair that inhibits hair growth– May reversible or persistant: topical steroids and
interferon• Alopecia can also occur secondary to treatment
• Overall primary cutaneous lymphoma, 65% are T-cell type, the most common is positive of CD4 immunotype
• CTCL diagnosis is based on clinical symptoms and course of the disease based on cyto & histomorphologic feature– Blood tests (CBC) & blood smear– Liver function, uric acid & LDH– Flowcytometri– HIV & HTLV-1– Skin biopsy: atypical lymphocytes with lymph node biopsy
especially in pts with lymphadenopathy• Histopathological exam of MF pts seen a superficial bandlike
or lichenoid infiltrates, which is dominated by lymphocytes & histiocytes.
Sezary syndrome diagnosis: > 1 of the following criteria– Sezary cell count ≥ 1000 cells/uL– Abnormalities of the immune phenotype– T-cell clones in peripheral blood, as indicated by
molecular and cytogenetic methods• Flowcytometri also used to determine the differential
diagnosis of precursor T-cell & peripheral T-cell & NK-cell lymphoma
– Examination of the skin biopsy
Staging is based on skin manifestations & extra cutaneous manifestations:Stage IA: patches / plaques <10% of skin surface area (T1)Stage IB: patches / plaques> 10% of skin surface area (T2)Stage II B: visible tumor (T3)Stage III: thorough erythrodermaStage IVA A1: erythroderma and significant blood disorders A2: lymph node biopsy showing atypical cellsStage IVB: involvement of organs (liver, lung & bone marrow)
In this pts also conducted abdominal US hepatomegaly although in examination no organomegaly was foundPlan for further exam to ensure the staging of diseaseBased on physical examination & investigation in this pts, the patient is diagnosed as cutaneous T-cell lymphoma, mycosis fungoides staging IVB
• Management– Early stage: topical therapy w/wo interferon-α or other
oral medications– Advanced stage: chemotherapy & current therapy
• Some cytotoxic regimen had palliative function but survival benefit is still questionable
• In pts with advanced lesions, the choice of therapy is systemic therapy– 2nd line therapy for pts with skin lesions– Retinoids (bexarotene), IFN-α, low-dose MTX, histone
deacetylase inhibitors (HDACi), or denileukin diftiox– Effective in refractory disease
• Low-dose MTX– oral every week, initial dose 20-30 mg/wks 60-70 mg/wks
• HDACi: vorinostat– Can be well tolerated by the oral administration– Side effects: fatigue, light-moderate thrombocytopenia, elevated creatinine,
can be given together with PUVA, IFN-α, MTX or in combination with chemotherapy
• Monoclonal antibodies: alemtuzumab– Targeting therapy against lymphocyte Ag– Systemic therapy for the provision of etoposide, vincristine, SF & prednisone
oral reported to respond to 80% at the advanced stage CTCL or refractory MF• Transplantation is recommended for refractory younger pts or
advanced stage with the unresponsive to IFN-α, bexarotene, HDACi or denileukin diftitox
• In this pts is planned to administrate chemotherapy, but the patient is not willing to get this treatment– Pts received MTX with symptomatic th/ of oral & topical treatment
• In the early stages of MF lymphoma cells is largely limited to the skin and has a good response with only topical therapy
• In pts who only had partially respond especially at an advanced stage, it takes a systemic therapy
• Sandwich effect:– Rationalization of combination skin & systemic th/
even in pts with limited skin abnormality– Skin therapy works from the outside & systemic
therapy works from the inside– Mutually reinforce one another effect
• MF is a condition that can’t be cured in most pts except stage IA
• Mortality & prognosis according to the stage of disease at the time of first diagnosis
• The involvement of lymph nodes, organs & transformation to large T-cell lymphoma have an aggressive clinical forms & usually die
• Condition of this pts isn’t experienced significant improvement– Pts didn’t get optimal th/ like systemic chemotherapy
THANK YOU